 SAN DIEGO BURLINGAME, Calif.--BUSINESS WIRE--Ajinomoto Bio-Pharma Services Aji Bio-Pharma, a leading provider of biopharmaceutical contract development and manufacturing services, and Humanigen, Inc. NASDAQ:HGEN Humanigen, a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumabTM, today announced the companies will be expanding their manufacturing agreement for the fill fini 